Year: 2025
Type: article
Study design: Observational Study
Abstract: Objective: A reduced treatment response to epoetin (EPO) therapy is a clinical challenge among hemodialysis (HD) patients.Outcomes of roxadustat in HD patients who had hyporesponse to EPO therapy were investigated. Materials and Methods:This retrospective study analyzed adult patients undergoing long-term HD.Hyporesponsiveness to EPO was defined as a hemoglobin (Hb) level consistently below 10 g/dL despite receiving maximum EPO and having adequate iron stores for at least three months.The target Hb threshold for following roxadustat was defined as ≥11 g/dL.Results: A total of 227 HD patients were screened, and 25 patients were enrolled.The mean age was 55.1±17.5 years.Median HD duration was 47 (19-118) months.Average Hb during the EPO treatment was 8.7±0.7 g/dL, compared to 9.8±1.3g/dL during the roxadustat treatment.Increased Hb following roxadustat was observed in 17 patients (68.0%).Target Hb was achieved in 14 (56%) patients following roxadustat.Erythropoietin resistance index was 17.6±1.4IU/kg/gHb in patients who responded to roxadustat, whereas it was 19.4±3.3IU/kg/gHb in non-responders (p=0.087).The average Hb level was significantly increased during the roxadustat period (p=0.011).Lower uric acid (p=0.003) and higher Kt/V (p=0.044) were observed in patients who achieved target Hb.Pre-treatment transferrin saturation was correlated with the amount of Hb change following roxadustat (p=0.034). Conclusion:The current study should be considered a pioneering effort, and findings support significant treatment success with roxadustat.
Source: Comprehensive Medicine
Author: Cihan Uysal
Institution: Ağrı Eğitim ve Araştırma Hastanesi
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7125530404